The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis

Eric M. Ruderman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

From the first use of biologic therapy for the management of rheumatoid arthritis, methotrexate (MTX) has been commonly used as co-therapy. There are a number of mechanistic reasons why MTX may improve the efficacy of biologics, including reduced antigenicity as well as reduced clearance of the biologic agent. Clinical trial data for tumor necrosis factor inhibitors and for other biologic agents does suggest added efficacy when these agents are used in combination with MTX. One exception may be the interleukin-6 receptor antibody tocilizumab, for which there is some data to suggest that monotherapy may be as effective as combined therapy with MTX. Post-marketing registry data also supports the concomitant use of MTX with biologics, with evidence for greater efficacy and longer persistence on treatment when compared with monotherapy.

Original languageEnglish (US)
Pages (from-to)S29-S32
JournalBulletin of the Hospital for Joint Diseases
Volume71
StatePublished - Nov 1 2013

ASJC Scopus subject areas

  • Surgery
  • Rheumatology
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this